TP53 and breast carcinoma: Although both are currently not targetable for breast cancer, TP53 is a gene very commonly mutated in both clonal hematopoiesis and tumors and is rarely representative of the germline Li–Fraumeni syndrome; consequently, routine germline testing may not be necessary for most patients with somatic TP53 mutations [20].